Medy-Tox Inc. (KOSDAQ:086900)

South Korea · Delayed Price · Currency is KRW

64,100

-1,800 (-2.73%)

Oct 12, 2026, 3:30 PM KST

Market Cap	413.97B -50.3%
Revenue (ttm)	251.08B +7.0%
Net Income	14.34B -20.2%
EPS	2,237.82 -21.2%
Shares Out	6.46M
PE Ratio	28.64
Forward PE	14.72
Dividend	1,200.00 (1.87%)
Ex-Dividend Date	Sep 29, 2025

Volume	16,923
Open	66,000
Previous Close	65,900
Day's Range	64,100 - 66,300
52-Week Range	64,100 - 141,100
Beta	0.39
Analysts	Hold
Price Target	92,000.00 (+43.53%)
Est. Earnings	Nov 13, 2026

About Medy-Tox

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hya... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2000

Employees 703

Stock Exchange KOSDAQ

Ticker Symbol 086900

Full Company Profile

Financial Performance

In 2025, Medy-Tox's revenue was 247.29 billion, an increase of 8.17% compared to the previous year's 228.62 billion. Earnings were 15.62 billion, a decrease of -2.26%.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for 086900 stock is "Hold." The 12-month stock price target is ₩92,000, which is an increase of 43.53% from the latest price.

Price Target

₩92,000

(43.53% upside)

Analyst Consensus: Hold

Stock Forecasts